Clinical trials: Chronic Graft Versus Host Disease
Chronic Graft vs. Host Disease, GVHD
Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease
Chronic graft-versus-host disease (cGVHD) is a condition that can develop after a stem cell transplant. It occurs when donor immune cells attack the body's tissues.
- Conditions
- Chronic Graft vs. Host Disease, GVHD, cGVHD, Graft Versus Host Disease in Skin
- Trial name
- NCT07728708
- Testing
- Axatilimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Acute Leukemia in Remission, Myelodysplastic Syndromes
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease…
- Conditions
- Acute Leukemia in Remission, Myelodysplastic Syndromes, Myeloproliferative Syndrome, Hodgkin Lymphoma
- Trial name
- TMF-Allo (NCT04935684)
- Testing
- Fecal Microbiota Transplantation
- Where
- 20 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Clermont-Ferrand
Chronic Graft Versus Host Disease
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease.
- Trial name
- NCT05996627
- Testing
- Belumosudil, Biospecimen Collection, Electronic Health Record Review
- Where
- 5 sites in United States
- Volunteers
- 82 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Graft Versus Host Disease
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Participants will be randomized 1:1 to receive either belumosudil or Best Available Therapy (BAT), with stratification based on baseline cGVHD severity as defined by the 2014◦NIH consensus criteria (moderate versus severe), use…
- Trial name
- NCT07771439
- Testing
- Belumosudil, Best available therapy (BAT)
- Volunteers
- 356 people
- Sponsor
- Sanofi
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Chronic Graft Versus Host Disease in Eye
Observational Cohort Study on Ocular Chronic Graft-Versus-Host Disease
This study is a multicenter, prospective, observational cohort study designed to enroll a total of 340 patients undergoing allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT07794800
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Ruijin Hospital
Chronic Graft Versus Host Disease
Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic graft-versus-host disease (cGVHD).
- Trial name
- NCT07127926
- Testing
- Belumosudil
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Graft Versus Host Disease
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
This is an open, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets in patients with chronic graft-versus-host disease
- Trial name
- NCT06300320
- Testing
- TQ05105 tablets
- Where
- 12 sites in China
- Volunteers
- 65 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Graft-versus-host-disease
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
This study will be conducted to compare Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
- Trial name
- NCT06821542
- Testing
- INCA034176, Best Available Therapy (BAT)
- Where
- 130 sites in Austria, Belgium and 14 more
- Volunteers
- 9 people
- Sponsor
- Incyte Corporation
Chronic Ocular Graft-versus-host Disease
Electrostimulation Study for Ocular Graft vs. Host Disease
This trial is testing to see if electrostimulation treatment (ET) will be effective in treating those with ocular Graft vs. Host Disease.
- Trial name
- NCT07166848
- Testing
- Electrodes with Currents, Electrodes without Currents
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Zhonghui K. Luo, MD, PhD
Chronic Graft-versus-host-disease
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
This study will be conducted to evaluate the safety, efficacy, and pharmacokinetics of axatilimab monotherapy in Chinese participants with recurrent or refractory active chronic graft-versus-host disease after systemic therapy.
- Trial name
- NCT06843408
- Testing
- INCA034176
- Where
- 9 sites in China
- Volunteers
- 32 people
- Sponsor
- Incyte Corporation
Chronic Graft-versus-host Disease (cGVHD)
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
Allogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approval for treatment of chronic GVHD that has failed 1-2 prior lines of…
- Trial name
- NCT06660355
- Testing
- Ruxolitinib, Prednisone
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Chronic Graft Versus Host Disease
Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants
The purpose of this open-label, randomized, cross-over, Phase 1, 2-treatment, 2-period, 2-sequence study is to assess the bioequivalence of belumosudil oral suspension compared with belumosudil tablet in healthy male participants…
- Trial name
- NCT07726914
- Testing
- Belumosudil
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Sanofi
Chronic Graft-Versus-Host Disease, Allogeneic Stem Cell Transplant
Psychosocial Mobile App for Chronic Graft-Versus-Host Disease
The purpose of this research study is to see whether a psychosocial mobile app called Horizons is effective at improving quality of life, symptom burden, psychological distress, and coping in patients living with chronic…
- Trial name
- NCT05690971
- Testing
- App, Usual Care
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Chronic Graft Versus Host Disease
Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
Graft versus Host Disease (GVHD) is frequent after allogeneic stem cell transplantation (alloSCT). GVHD occurs following 2 patterns : acute GVHD (aGVHD) or chronic GVHD (cGVHD).
- Trial name
- TIL-GVHD (NCT06247150)
- Testing
- Additional blood sample, cGVHD target tissue biopsy
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Bordeaux
Non-sclerotic Cutaneous Chronic Graft-versus-host Disease
Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease
The purpose of this study is to compare the safety and effects of ruxolitinib 1.5% cream with those of standard moisturizers in people with non-sclerotic chronic cutaneous GVHD.
- Trial name
- NCT03954236
- Testing
- topical ruxolitinib 1.5% cream, Topical vehicle/moisturizer cream
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Graft Versus Host Disease
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study
This trial collects clinical data and blood samples to predict the quality of response to specific treatments in patients with chronic graft-versus-host disease (cGVHD) who are about to start a new therapy.
- Trial name
- NCT04431479
- Testing
- Biospecimen Collection, Medical Chart Review, Quality-of-Life Assessment
- Where
- 10 sites in United States, Canada
- Volunteers
- 211 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Graft Vs. Host Disease
Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
- Trial name
- NCT05544032
- Testing
- axatilimab
- Sponsor
- Incyte Corporation
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
This phase II trial studies how well vedolizumab plus post-transplant cyclophosphamide (PTCy) and short course tacrolimus work for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease
- Trial name
- NCT06815003
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans)
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
This is a mutli-center open-label study to provide continued supply of itacitinib to participants from the following Incyte-sponsored studies of itacitinib: INCB39110-209, INCB39110-213, INCB39110-214, INCB39110-230, and…
- Conditions
- Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host Disease
- Trial name
- NCT04640025
- Testing
- itacitinib
- Where
- 21 sites in United States, Austria and 7 more
- Volunteers
- 18 people
- Sponsor
- Incyte Corporation